RST will produce a kit for clinical use. Current methods for detecting Herpes Zoster virus do not have the combination of features and benefits RST can offer. Unlike existing products, we test saliva as opposed to blood or cerebrospinal fluid. Our test is therefore much less invasive. Any potentially infectious sample is contained in the completely disposable kit, which is discarded at the end of the test. Our test will be self-contained requiring no capitol equipment. RST kit is based on antibody specificity. This creates the opportunity to configure the kit to detect a massive range of targets by simply changing the antibodies. Other disease agents, biological warfare agents and environmental pollutants are examples of the different types of molecular targets we could configure our kits to detect. RST kits will require no electrical power and can be used in remote locations.
The primary NASA innovation is an in situ assay kit that provides (1) real-time assessment of immune function (2) early warning of pilot susceptibility to infectious disease (3) the opportunity to learn how time in space relates to weakening of immune defenses (4) the capability to map genetic markers that indicate resistance to the effects of time in space on compromising immune function (5) data that will allow for the correlation of specific environmental variables with weakening of the immune system (6) a chance to evaluate specific counter measures designed to protect and preserve the integrity of immune defense. The innovation would enable scientists to better understand the risks of prolonged space exploration and to develop strategies to protect astronauts on long journeys. We believe we are beginning at about TRL 3 in Phase I and plan to advance the technology to TRL 6 by the end of Phase II.
More »